Athera begins Phase IIa trial of PC-mAb for arterial inflammation

Athera Biotechnologies AB (Stockholm, Sweden) began a Phase IIa trial of once-monthly IV PC-mAb to treat arterial inflammation in patients with elevated levels of lipoprotein(a) (LPA).

The double-blind, placebo-controlled, European trial's primary endpoint is monocyte function assessed ex vivo. Secondary endpoints include arterial inflammation assessed in vivo, arterial wall stiffness and safety...